PMN Jumps 27.3% on EPS Revision and Alzheimer's Trial Data; KNSA, NDLS Follow
ProMIS Neurosciences (PMN) surged 27.3% after its EPS growth estimate was revised to 27.1% and positive Alzheimer's trial safety data reinforced the outlook. Kiniksa (KNSA) gained 24.0% following a 39.7% EPS growth estimate revision and strong Q2 earnings. Noodles & Company (NDLS) added 23.4% after a massive EPS growth estimate jump from 184.1% to 309.1%.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| PMN | Healthcare | 2026-07-27 | N/A | +27.3% |
| KNSA | Healthcare | 2026-07-23 | N/A | +24.0% |
| NDLS | Consumer Cyclical | 2026-07-27 | +125.0pp | +23.4% |
| BZUN | Consumer Cyclical | 2026-07-24 | +2.2pp | +20.2% |
| ATEC | Healthcare | 2026-07-23 | N/A | +17.7% |
Why did PMN stock jump in July 2026?
PMN jumped 27.3% (from $11.72 to $14.92) after analysts raised its forward EPS growth estimate to 27.1% on July 27.
The revision was reinforced the next day by positive interim safety results from its PRECISE-AD Phase 1b Alzheimer's trial, which showed no ARIA-E cases and favorable biomarker trends including a reduction in plasma pTau217 in 68.5% of patients. The strong safety profile and biomarker data supported continued development of PMN310, boosting investor confidence beyond the EPS upgrade.
PMN EPS revision history → · Screener snapshot from 2026-07-27 →
FAQ: PMN
Why did PMN stock jump in July 2026?
PMN surged 27.3% after its EPS growth estimate was raised to 27.1% and positive interim Alzheimer's trial safety data was released on July 28.
Is PMN a buy after the rally?
With a 27.1% EPS growth estimate and favorable biomarker trends, PMN may have upside, but further trial results are key.
What caused PMN's surge?
The surge was driven by an upward EPS revision and promising safety data showing no ARIA-E in its Alzheimer's drug trial.
Why did KNSA stock jump in July 2026?
KNSA jumped 24.0% (from $63.05 to $78.20) after analysts raised its forward EPS growth estimate to 39.7% on July 23.
The revision was validated by a stellar Q2 earnings report on July 28, with ARCALYST net revenue rising 55% year-over-year to $243.6 million and full-year sales guidance raised to $980–$995 million. The strong commercial execution and initiation of the pivotal PASTORALE trial for KPL-387 further underpinned the growth outlook.
KNSA EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: KNSA
Why did KNSA stock jump?
KNSA rose 24% after its EPS growth estimate was revised to 39.7%, following a strong Q2 earnings beat and raised ARCALYST guidance.
Is KNSA a buy after the rally?
With 55% revenue growth and a 39.7% EPS growth estimate, KNSA is attractive but valuation is elevated.
What caused KNSA's surge?
The surge resulted from an EPS revision and Q2 results showing net product revenue of $243.6M, up 55% year over year.
Why did NDLS stock jump in July 2026?
NDLS jumped 23.4% (from $14.25 to $17.58) after analysts raised its forward EPS growth estimate from 184.1% to 309.1% on July 27.
This 125-percentage-point upward revision, the largest among today's screeners, signaled an expected dramatic earnings turnaround at Noodles & Company, likely driven by improving operational efficiencies or cost controls. No specific news emerged, making the massive estimate revision the primary catalyst.
NDLS EPS revision history → · Screener snapshot from 2026-07-27 →
FAQ: NDLS
Why did NDLS stock jump?
NDLS gained 23.4% after its EPS growth estimate was revised from 184.1% to 309.1%, a 125-point increase.
Is NDLS a buy after the rally?
The massive revision indicates strong expected earnings growth, but lack of news may add uncertainty.
What is NDLS's EPS growth estimate?
NDLS's forward EPS growth estimate is now 309.1%, up from 184.1%.
Why did BZUN stock jump in July 2026?
BZUN jumped 20.2% (from $2.48 to $2.98) after analysts raised its forward EPS growth estimate from 58.1% to 60.4% on July 24.
Despite the modest 2.2pp revision, the stock rallied sharply, likely reflecting renewed investor confidence in Baozun's earnings recovery within a favorable macro environment for Chinese consumer cyclical stocks. No company-specific news accompanied the move.
BZUN EPS revision history → · Screener snapshot from 2026-07-24 →
FAQ: BZUN
Why did BZUN stock jump?
BZUN rose 20.2% after its EPS growth estimate was raised from 58.1% to 60.4% on July 24.
Is BZUN a buy after the rally?
The 60.4% EPS growth estimate suggests recovery, but the small revision size and no news warrant caution.
What caused BZUN's surge?
The rally was triggered by an upward EPS revision, likely amplified by positive sentiment in Chinese consumer stocks.
Why did ATEC stock jump in July 2026?
ATEC jumped 17.7% (from $8.21 to $9.66) after analysts raised its forward EPS growth estimate to 83.2% on July 23.
The upward revision reflected strong expectations for earnings expansion at Alphatec, a medical device maker focused on spinal surgery products, likely due to increasing procedure volumes or market share gains. No specific news emerged, but the high growth rate estimate attracted investors.
ATEC EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: ATEC
Why did ATEC stock jump?
ATEC gained 17.7% after its EPS growth estimate was set at 83.2% on July 23.
Is ATEC a buy after the rally?
With an 83.2% EPS growth estimate, ATEC is positioned for strong earnings expansion, but medical device sector risks exist.
What caused ATEC's surge?
The surge followed an upward EPS revision, with no specific news, likely due to demand for spinal surgery products.
Today's top performers highlight how upward EPS estimate revisions, especially large-magnitude changes like NDLS's 125-point jump, can drive significant price rallies even without other catalysts. Healthcare stocks PMN, KNSA, and ATEC show that EPS upgrades paired with positive news or earnings beats are powerful price drivers.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →